Literature DB >> 2230268

Seroprevalence of human T cell leukemia viruses in selected populations of homosexual men.

R D Meyer1, T Moudgil, R Detels, J P Phair, M S Hirsch, D D Ho.   

Abstract

This study sought to define the seroprevalence of human T cell leukemia virus (HTLV) types I and II in selected populations of homosexual men. Serum specimens were screened for antibodies to HTLV and to human immunodeficiency virus (HIV) by enzyme immunoassay; successive testing of specimens with positive results was done by Western blotting and radioimmunoprecipitation assay (RIPA) and then by polymerase chain reaction (PCR) assay on available peripheral blood mononuclear cells (PBMC). Of 1290 specimens, only 4 had antibodies against HTLV confirmed by RIPA. PCR analysis of DNA from PBMC from two subjects showed one to be HTLV-I and the other to be HTLV-II; both men also had HIV antibodies. These results demonstrate a lower seroprevalence rate for HTLV than some previous studies and emphasize the need for specific confirmatory tests.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230268     DOI: 10.1093/infdis/162.6.1370

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Risk factors for HTLV-II infection in Peruvian men who have sex with men.

Authors:  Joseph R Zunt; Alberto M La Rosa; Jesús Peinado; Javier R Lama; Luis Suarez; Monica Pun; Cesar Cabezas; Jorge Sanchez
Journal:  Am J Trop Med Hyg       Date:  2006-05       Impact factor: 2.345

2.  Retroviral infection in Peruvian men who have sex with men.

Authors:  Alberto M La Rosa; Joseph R Zunt; Jesus Peinado; Javier R Lama; Thanh G N Ton; Luis Suarez; Monica Pun; Cesar Cabezas; Jorge Sanchez
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

Review 3.  HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review.

Authors:  Daniel Bradshaw; Graham Philip Taylor
Journal:  Front Med (Lausanne)       Date:  2022-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.